For a patient with HER2‑positive breast cancer who received neoadjuvant chemotherapy with trastuzumab and now has postoperative pathology of ypT1b N0, what adjuvant therapy is recommended after surgery?

Adjuvant Therapy for HER2+ Breast Cancer with ypT1bN0 After Neoadjuvant Trastuzumab

Continue trastuzumab to complete 1 year total of HER2-directed therapy, as this patient has residual invasive disease after neoadjuvant therapy with trastuzumab alone (without pertuzumab). 1, 2

Treatment Algorithm Based on Pathologic Response

Your patient has residual invasive disease (ypT1bN0) after neoadjuvant chemotherapy with trastuzumab. The critical decision point is whether dual HER2 blockade (trastuzumab + pertuzumab) was used during neoadjuvant therapy:

If Neoadjuvant Therapy Was Trastuzumab ALONE:

Complete 1 year total of trastuzumab therapy (Category 1 recommendation) 3, 2, 4

• Calculate total duration from start of neoadjuvant therapy
• Continue until 18 cycles (approximately 1 year) are completed
• Can be administered concurrently with radiation therapy and endocrine therapy if HR-positive 3

If Neoadjuvant Therapy Included Dual Blockade (Trastuzumab + Pertuzumab):

Switch to T-DM1 (ado-trastuzumab emtansine) for 14 cycles (Category 1 recommendation) 1, 2

• This is based on the KATHERINE trial showing significantly improved invasive disease-free survival with T-DM1 versus trastuzumab in patients with residual disease after neoadjuvant dual blockade 1
• If T-DM1 is discontinued for toxicity, complete 1 year of HER2-directed therapy with trastuzumab ± pertuzumab 2

Key Clinical Considerations

Hormone Receptor Status Matters:

• If ER/PR-positive: Add adjuvant endocrine therapy (Category 1) 2
• Endocrine therapy should be given sequentially after chemotherapy or concurrently with HER2-targeted therapy 3
• Consider extended adjuvant neratinib (1 year) following trastuzumab-based therapy for HR+/HER2+ disease with high recurrence risk 1, 2

Risk Stratification:

This patient has favorable pathologic features (small residual tumor, node-negative), which suggests lower recurrence risk compared to those with larger residual disease or node-positive status 1. However, the presence of any residual invasive disease after neoadjuvant therapy indicates need for continued HER2-directed therapy.

Common Pitfalls to Avoid

1. Don't stop HER2-directed therapy early: The standard is 1 year total duration from initiation of neoadjuvant therapy 4

2. Don't use T-DM1 if only single-agent trastuzumab was given neoadjuvantly: T-DM1's benefit was demonstrated specifically in patients who received dual HER2 blockade and still had residual disease 1, 2

3. Don't give trastuzumab concurrently with anthracyclines: If additional chemotherapy is needed, avoid concurrent anthracycline-trastuzumab due to cardiotoxicity risk 4

4. Monitor cardiac function regularly: Assess LVEF before each treatment phase and at regular intervals 4

Monitoring During Adjuvant Therapy

• Regular cardiac function assessments (LVEF) 4
• Monitor for infusion reactions, particularly with first doses
• If HR-positive, ensure endocrine therapy is initiated appropriately
• Consider bisphosphonate therapy for 3-5 years if postmenopausal with high-risk features 2

The evidence strongly supports completing a full year of HER2-directed therapy in all patients with HER2-positive breast cancer who received neoadjuvant treatment, with the specific agent (trastuzumab vs T-DM1) determined by whether dual blockade was used neoadjuvantly and whether residual disease is present 1, 2, 4.